| Q40572125 | A multicenter study of anaplastic oligodendroglioma: the Korean Radiation Oncology Group Study 13-12. |
| Q53804058 | Adjuvant nitrosoureas: will they ever go away? |
| Q24194645 | Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas |
| Q92446759 | Anaplastic astrocytoma and non-1p/19q co-deleted anaplastic oligoastrocytoma: long-term survival, employment, and performance status of survivors |
| Q39246821 | Anaplastic glioma |
| Q38456018 | Anaplastic glioma: current treatment and management |
| Q39373950 | Anaplastic oligodendroglioma: a new treatment paradigm and current controversies |
| Q39480039 | Anaplastic oligodendroglioma: advances and treatment options. |
| Q39556985 | Biomarkers classification and therapeutic decision-making for malignant gliomas |
| Q26801254 | Clinical management of grade III oligodendroglioma |
| Q33815954 | Clinical prognostic factors of adjuvant radiation therapy for low-grade gliomas: results of 10 years survival |
| Q40008535 | Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers |
| Q38243100 | Cranial and spinal oligodendrogliomatosis: a case report and review of the literature |
| Q49317056 | Current therapeutic approaches to diffuse grade II and III gliomas. |
| Q37429161 | Deferred radiotherapy and upfront procarbazine-ACNU-vincristine administration for 1p19q codeleted oligodendroglial tumors are associated with favorable outcome without compromising patient performance, regardless of WHO grade |
| Q35789635 | Detection of 1p19q deletion by real-time comparative quantitative PCR. |
| Q39005975 | Determining optimal treatment strategy for diffuse glioma: the emerging role of IDH mutations. |
| Q38461565 | Diagnostic, prognostic and predictive relevance of molecular markers in gliomas |
| Q60923732 | Differences in patterns of care and outcomes between grade II and grade III molecularly defined 1p19q co-deleted gliomas |
| Q50042050 | Does intensification of chemotherapy in anaplastic oligodendrogliomas still have a role? |
| Q91878200 | Educational Case: Histologic and Molecular Features of Diffuse Gliomas |
| Q90626835 | Eighty percent survival rate at 15 years for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade |
| Q39291912 | European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. |
| Q33411366 | Fotemustine: a third-generation nitrosourea for the treatment of recurrent malignant gliomas |
| Q43619655 | Hypoxia-inducible factor-1-regulated protein expression and oligodendroglioma patient outcome: comparison with established biomarkers and preoperative UCSF low-grade scoring system |
| Q89471305 | Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study |
| Q30419123 | Initial treatment patterns over time for anaplastic oligodendroglial tumors |
| Q38390616 | Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide |
| Q48295109 | Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics. |
| Q47732901 | Modulated Radiotherapy with Concurrent and Adjuvant Temozolomide for Anaplastic Gliomas: Indian Single-center Data |
| Q28383205 | Molecular Markers in Low-Grade Glioma-Toward Tumor Reclassification |
| Q41890894 | Moving toward molecular classification of diffuse gliomas in adults |
| Q92446227 | Neuro-Oncology Clinical Debate: PCV or temozolomide in combination with radiation for newly diagnosed high-grade oligodendroglioma |
| Q43733606 | Neuro-oncology: anaplastic oligodendrogliomas-value of early chemotherapy. |
| Q54948216 | Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis. |
| Q39453835 | PCV for anaplastic oligodendrogliomas: back to the future or a step backwards? A point/counterpoint discussion |
| Q48457980 | Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population: the Korean Radiation Oncology Group study 13-12. |
| Q38268897 | Pharmacologic therapies for malignant glioma: a guide for clinicians. |
| Q30542081 | Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. |
| Q92446013 | Pivotal therapeutic trials for infiltrating gliomas and how they affect clinical practice |
| Q55042008 | Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation. |
| Q38626948 | Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen? |
| Q37588272 | Prognostic value and their clinical implication of 89-gene signature in glioma |
| Q30370204 | Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors |
| Q88483360 | Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas |
| Q45975426 | Response to Weltman and Fleury Malheiros, re Lassman et al. |
| Q48147847 | SEOM clinical guidelines for anaplastic gliomas (2017). |
| Q48250296 | Success at last: a molecular factor that informs treatment |
| Q59809879 | The Dilemma of Cure and Damage in Oligodendroglioma: Ways to Tip the Balance Away from the Damage |
| Q38921975 | The Role of Molecular Diagnostics in the Management of Patients with Gliomas |
| Q53050275 | The cyclin-like protein Spy1 regulates growth and division characteristics of the CD133+ population in human glioma. |
| Q35114090 | The future of high-grade glioma: Where we are and where are we going |
| Q37986511 | The impact of chemotherapy on cognitive outcomes in adults with primary brain tumors |
| Q47133444 | Treatment Recommendations for Adult Patients with Diffuse Gliomas of Grades II and III According to the New WHO Classification in 2016. |
| Q48160976 | Upfront chemotherapy and subsequent resection for molecularly defined gliomas |